SG11201609652RA - Treatment of polybacterials infections - Google Patents
Treatment of polybacterials infectionsInfo
- Publication number
- SG11201609652RA SG11201609652RA SG11201609652RA SG11201609652RA SG11201609652RA SG 11201609652R A SG11201609652R A SG 11201609652RA SG 11201609652R A SG11201609652R A SG 11201609652RA SG 11201609652R A SG11201609652R A SG 11201609652RA SG 11201609652R A SG11201609652R A SG 11201609652RA
- Authority
- SG
- Singapore
- Prior art keywords
- polybacterials
- infections
- treatment
- polybacterials infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1214—Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014506P | 2014-06-19 | 2014-06-19 | |
| US201562140849P | 2015-03-31 | 2015-03-31 | |
| PCT/US2015/036576 WO2015196011A1 (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201609652RA true SG11201609652RA (en) | 2016-12-29 |
Family
ID=54936121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609652RA SG11201609652RA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
| SG10201811361XA SG10201811361XA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811361XA SG10201811361XA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11168132B2 (enExample) |
| EP (1) | EP3157565B1 (enExample) |
| JP (2) | JP6845016B2 (enExample) |
| KR (1) | KR102549870B1 (enExample) |
| CN (1) | CN106456767B (enExample) |
| AU (1) | AU2015276938B2 (enExample) |
| CA (1) | CA2952278A1 (enExample) |
| ES (1) | ES2983252T3 (enExample) |
| SG (2) | SG11201609652RA (enExample) |
| TW (1) | TWI719938B (enExample) |
| WO (1) | WO2015196011A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2838211C (en) | 2011-06-10 | 2023-08-01 | Medimmmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
| HUE050985T2 (hu) | 2011-11-07 | 2021-01-28 | Medimmune Ltd | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák |
| KR20150092738A (ko) | 2012-11-06 | 2015-08-13 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| CN104968797B (zh) * | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
| EP3383884A4 (en) | 2015-11-30 | 2019-07-31 | Medimmune Limited | PROCESS FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA |
| AU2017261374B2 (en) | 2016-05-05 | 2024-06-20 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs for use against pseudomonas aeruginosa |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| WO2020076789A2 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| EP3864040A1 (en) | 2018-10-09 | 2021-08-18 | Medimmune, LLC | Antibodies directed against staphylococcus aureus leukotoxins |
| GB201816554D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| WO2020172233A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Treatment of prostate cancer by androgen ablation and il-8 blockade |
| TW202100549A (zh) * | 2019-03-13 | 2021-01-01 | 美商麥迪紐有限責任公司 | 降低金黃色葡萄球菌在定殖的患者中之感染 |
| CN113966343A (zh) * | 2019-06-11 | 2022-01-21 | 瑞泽恩制药公司 | 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 |
| US20220259290A1 (en) * | 2019-07-24 | 2022-08-18 | Japan Science And Technology Agency | Innovative production technique for antibody-enzyme |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| WO2025117765A1 (en) * | 2023-12-01 | 2025-06-05 | University Of Washington | Protective monoclonal antibodies to pseudomonas aeruginosa |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2719397A1 (en) | 2006-06-12 | 2014-04-16 | GlaxoSmithKline Biologicals SA | Use of alpha-toxin for treating and preventing staphylococcus infections |
| JP2013515079A (ja) * | 2009-12-22 | 2013-05-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 |
| SG10201913690SA (en) | 2011-02-08 | 2020-03-30 | Medimmune Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| HUE050985T2 (hu) * | 2011-11-07 | 2021-01-28 | Medimmune Ltd | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák |
| KR20150092738A (ko) | 2012-11-06 | 2015-08-13 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| CN104968797B (zh) | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
| KR20150082367A (ko) * | 2012-11-06 | 2015-07-15 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법 |
| WO2017075188A2 (en) | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
-
2015
- 2015-06-18 TW TW104119861A patent/TWI719938B/zh active
- 2015-06-19 SG SG11201609652RA patent/SG11201609652RA/en unknown
- 2015-06-19 JP JP2016573926A patent/JP6845016B2/ja active Active
- 2015-06-19 CN CN201580032548.7A patent/CN106456767B/zh active Active
- 2015-06-19 CA CA2952278A patent/CA2952278A1/en active Pending
- 2015-06-19 KR KR1020167034742A patent/KR102549870B1/ko active Active
- 2015-06-19 ES ES15809174T patent/ES2983252T3/es active Active
- 2015-06-19 US US15/319,958 patent/US11168132B2/en active Active
- 2015-06-19 SG SG10201811361XA patent/SG10201811361XA/en unknown
- 2015-06-19 AU AU2015276938A patent/AU2015276938B2/en active Active
- 2015-06-19 WO PCT/US2015/036576 patent/WO2015196011A1/en not_active Ceased
- 2015-06-19 EP EP15809174.4A patent/EP3157565B1/en active Active
-
2020
- 2020-12-18 JP JP2020209896A patent/JP2021063090A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11168132B2 (en) | 2021-11-09 |
| CN106456767B (zh) | 2021-07-09 |
| JP2017519768A (ja) | 2017-07-20 |
| AU2015276938A1 (en) | 2017-01-05 |
| CA2952278A1 (en) | 2015-12-23 |
| CN106456767A (zh) | 2017-02-22 |
| TW201613575A (en) | 2016-04-16 |
| KR20170015329A (ko) | 2017-02-08 |
| US20170129943A1 (en) | 2017-05-11 |
| AU2015276938B2 (en) | 2020-11-19 |
| WO2015196011A1 (en) | 2015-12-23 |
| KR102549870B1 (ko) | 2023-06-29 |
| EP3157565A1 (en) | 2017-04-26 |
| EP3157565B1 (en) | 2024-04-24 |
| EP3157565A4 (en) | 2018-03-21 |
| JP2021063090A (ja) | 2021-04-22 |
| JP6845016B2 (ja) | 2021-03-17 |
| TWI719938B (zh) | 2021-03-01 |
| ES2983252T3 (es) | 2024-10-22 |
| SG10201811361XA (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252839A0 (en) | Treatment of boils | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| GB201701673D0 (en) | Methods of well treatment | |
| PL3212174T3 (pl) | Sposoby leczenia zakażeń wirusem filoviridae | |
| SG11201702688UA (en) | Methods of treating rsv infections | |
| GB201502137D0 (en) | Treatment | |
| GB201410116D0 (en) | Method of treatment | |
| IL246880A0 (en) | Tumor treatment | |
| SG11201610243YA (en) | Treatment of severe hypertriglyceridemia | |
| IL253028A0 (en) | treatment method | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201519450D0 (en) | Novel treatment | |
| IL255498A (en) | Treatment of pruritus | |
| GB201408297D0 (en) | Treatment of cancer | |
| GB201402909D0 (en) | Treating infection | |
| EP3091985A4 (en) | Treatment of migraines | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201411027D0 (en) | Treatment | |
| GB201512139D0 (en) | Methods of treatment | |
| EP3122363A4 (en) | Treatment of autism | |
| GB201412411D0 (en) | Treatment | |
| GB201407806D0 (en) | Treatment of fibrosis | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201522257D0 (en) | Treatment of autism | |
| GB201421980D0 (en) | Method of treatment |